Entering text into the input field will update the search result below

Gilead's (NASDAQ:GILD) tenofovir alafenamide fumarate (TAF) treatment for HIV-1 met its primary...

Oct. 31, 2012 9:28 AM ETGilead Sciences, Inc. (GILD) StockGILDBy: Yigal Grayeff, SA News Editor1 Comment

Gilead's (NASDAQ:GILD) tenofovir alafenamide fumarate (TAF) treatment for HIV-1 met its primary objective in a Phase II trial in which, in combination with other drugs, it went up against Stribild, also from Gilead. With TAF achieving a similar virological response to Stribild, the company now plans to undertake further studies. (PR)

Recommended For You

About GILD Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GILD--
Gilead Sciences, Inc.